Dataset Information


Remarkable Response of EGFR- and HER2-Amplified Metastatic Colon Cancer to Pyrotinib After Failed Multiline Treatments: A Case Report and Literature Review.

ABSTRACT: Human epidermal growth factor receptor 2 (HER2) has been verified as a valuable biomarker and treatment target in metastatic colorectal cancer (mCRC). Pyrotinib, a novel irreversible HER2/epidermal growth factor receptor (EGFR) dual tyrosine kinase inhibitor, can efficiently inhibit the proliferation of HER2-positive cancer cells in many tumors. We report a case of a 40-year-old woman with both HER2- and EGFR-amplified metastatic colon cancer, who developed refractory disease resistant to multiline therapies (including trastuzumab with lapatinib) but achieved a remarkable response after pyrotinib treatment. For patients with HER2-positive mCRC, who have developed resistance to trastuzumab and lapatinib, pyrotinib is a promising new candidate, which can be used as salvage therapy.


PROVIDER: S-EPMC7649345 | BioStudies | 2020-01-01

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC7577809 | BioStudies
2019-01-01 | S-EPMC6834479 | BioStudies
2018-01-01 | S-EPMC6163141 | BioStudies
2020-01-01 | S-EPMC7359576 | BioStudies
2020-01-01 | S-EPMC7468538 | BioStudies
2020-01-01 | S-EPMC7640366 | BioStudies
2020-01-01 | S-EPMC7812178 | BioStudies
2020-01-01 | S-EPMC7263174 | BioStudies
2020-01-01 | S-EPMC7342492 | BioStudies
2019-01-01 | S-EPMC6549349 | BioStudies